Randomized phase 3 study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitornaive, ret-mutant medullary thyroid cancer

被引：0

作者：

Hadoux, Julien ^{[1
]}

Elisei, Rosella ^{[2
]}

Brose, Marcia ^{[3
]}

Hoff, Ana ^{[4
]}

Robinson, Bruce ^{[5
]}

Gao, Ming ^{[6
]}

Jarzab, Barbara ^{[7
]}

Isaev, Pavel ^{[8
]}

Kopeckova, Katerina ^{[9
,10
]}

Wadsley, Jonathan ^{[11
]}

Fuehrer, Dagmar ^{[12
]}

Keam, Bhumsuk ^{[13
]}

Sherman, Eric ^{[14
]}

Tahara, Makoto ^{[15
]}

Hu, Mimi ^{[16
]}

Lin, Yan ^{[17
]}

Maeda, Patricia ^{[17
]}

Wirth, Lori ^{[18
]}

Capdevila, Jaume ^{[19
]}

机构：

[1] Gustave Roussy, Villejuif, France

[2] Univ Pisa, Dept Clin & Expt Med, Endocrine Unit, Pisa, Italy

[3] Sidney Kimmel Med Coll, Philadelphia, PA USA

[4] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[5] Western Sydney Univ, Sch Med, Campbelltown, Australia

[6] Tianjin Canc Inst & Hosp, Tianjin, Peoples R China

[7] Maria Sklodowska Curie Natl Res Inst Oncol, Gliwice Branch, Dept Nucl Med & Endocrine Oncol, Gliwice, Poland

[8] Fed State Inst Med Radiol Res Ctr, Obninsk, Russia

[9] Charles Univ Prague, Fac Med 2, Dept Oncol, Prague, Czech Republic

[10] Motol Univ Hosp, Prague, Czech Republic

[11] NHS Fdn Trust, Weston Pk Canc Ctr, Clin Oncol Dept, Shefflied, England

[12] Univ Duisburg Essen, Univ Hosp Essen, Endocrine Tumour Ctr, West German Canc Ctr,Dept Endocrinol Diabetol & M, Essen, Germany

[13] Seoul Natl Univ Hosp, Seoul, South Korea

[14] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, New York, NY USA

[15] Natl Canc Ctr Hosp East, Kashiwa, Japan

[16] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[17] Eli Lilly & Co Corp Ctr, Indianapolis, IN USA

[18] Massachusetts Gen Hosp, Boston, MA USA

[19] Univ Autonoma Barcelona, Vall dHebron Inst Oncol, Med Oncol Dept, Barcelona, Spain

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1133

引用

页码：228 / 228

页数：1